{"schema_version":"secwatch.filing_event.v1","accession":"0001601485-26-000041","form_type":"8-K","ticker":"ELTX","cik":"0001601485","company_name":"Elicio Therapeutics, Inc.","filed_at":"2026-05-11T20:09:10+00:00","discovered_at":"2026-05-11T20:11:00.398083+00:00","generated_at":"2026-05-11T22:28:04.103916+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Q1 net loss $11.8M ($0.65/sh); Phase 2 DFS readout mid-2026; cash runway into Q4","bullets":["Q1 net loss $11.8M ($0.65/sh) vs $11.2M ($0.87/sh) YoY; R&D $6.8M, G&A $3.8M.","Cash $14.9M at Mar 31; raised $13M via ATM in Q1-Q2; expected runway into Q4 2026.","Phase 2 AMPLIFY-7P primary DFS analysis for ELI-002 7P in PDAC expected mid-2026; fewer events observed.","Company remains blinded; after DFS readout, plans End-of-Phase 2 FDA meeting for Phase 3 design."],"urls":{"canonical":"https://secwatch.observer/filing/0001601485-26-000041","json":"https://secwatch.observer/filing/0001601485-26-000041.json","markdown":"https://secwatch.observer/filing/0001601485-26-000041.md","text":"https://secwatch.observer/filing/0001601485-26-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000041/0001601485-26-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601485/000160148526000041/eltx-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:28:04.103916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}